RAPID CASE ASCERTAINMENT SHARED RESOURCE (RCA) PROJECT SUMMARY/ABSTRACT The Rapid Case Ascertainment program (RCA) was originally developed in 1986-1987 in response to a Connecticut Hospital Association (CHA) request to establish a single entity that would be responsible for all population-based cancer epidemiology studies that directly involve Connecticut hospitals. RCA assists cancer researchers in implementing and executing their studies by providing high-quality and cost-effective study management, cancer case identification, patient enrollment and interview, medical record abstraction, and pathology specimen collection services so that investigators can accomplish their scientific goals. During our most recent funding period (FY17), 19 people have used RCA. Thirteen of these users (68%) were YCC members. The majority of this use came from Cancer Prevention and Control (CPC) Research Program. The Rapid Case Ascertainment Shared Resource (RCA) facilitates cancer research and population-based studies of cancer for YCC investigators, as well as outside investigators, who wish to conduct research in the state of Connecticut (YCC catchment area). RCA addresses the many administrative tasks common to all proposed hospital-based research in the state and provides a uniformly high-quality, well-coordinated interface with those individuals, institutions, and agencies crucial to the success of cancer research. RCA also supports rapid cancer case identification for research and clinical purposes. RCA functions as an agent of the Connecticut Tumor Registry, as designated by the Commissioner of Public Health. RCA is led by Rajni Mehta who has a master?s degree in Public Health.
The Specific Aims of the RCA Shared Resource are to: (1) Provide consultation and assistance to investigators in protocol writing in appropriate areas (protection of human subjects, HIPAA regulations, confidentiality, etc.); (2) Obtain approvals to conduct the research and submit annual reports and requests for re-approvals to all non-Yale IRBs; (3) Identify patients with incident cancers; (4) Serve as an honest broker in studies that require the investigators to not know the identity or the individuals whose data or specimens are being used for research (de-identified research); (5) Perform data collection and pathology specimen collection; (6) Facilitate research across the state of CT (YCC catchment area), as well as targeting areas of higher cancer risk (e.g., cities of Hartford, New Haven. and Bridgeport).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989591
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564

Showing the most recent 10 out of 675 publications